Chimeric Adenoviruses Enhancing Oncolytic Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current adenoviral therapies for cancer treatment, particularly using Ad5, lack potency and selectivity for tumor cells, necessitating the development of more effective oncolytic adenoviruses that can target specific tumor types with enhanced therapeutic indices.
Innovation Solution
Creation of chimeric adenoviruses with genomes comprising nucleic acid sequences from distinct adenoviral serotypes within subgroups B, C, D, E, or F, specifically designed to be oncolytic and demonstrate an enhanced therapeutic index by combining regions such as E2B, fiber, hexon, and penton proteins, and potentially rendering them replication deficient to enhance tumor cell targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Ad5-based adenoviruses are used for cancer treatment, then the therapy has established clinical protocols and production methods, but the potency and selectivity for tumor cells is insufficient
Solution Approach 1:
The patent combines genetic material from multiple adenoviral serotypes (e.g., Ad5 E1A region with Ad2 E2B region) to create chimeric adenoviruses that inherit advantageous properties from each parent serotype, thereby achieving both clinical reliability and enhanced tumor cell potency
Solution Approach 2:
The patent modifies specific regions of the adenoviral genome (such as E1A, E2B, fiber, hexon) while maintaining other regions unchanged, allowing localized optimization of tumor targeting and cytolytic activity without compromising overall viral stability or clinical manufacturability
2Adaptability or versatility
If adenoviral therapy is designed to target specific tumor cells, then selectivity improves, but the complexity of viral construction increases
Solution Approach 1:
The patent divides the adenoviral genome into functional modules (E1A, E2B, fiber, hexon, penton) that can be independently selected and combined from different serotypes, simplifying the construction process despite the need for high specificity
Solution Approach 2:
The patent uses universal adenoviral backbone structures and standardized cloning strategies that can accommodate different serotype combinations, reducing construction complexity while maintaining the ability to target various tumor types
3Productivity
If chimeric adenoviruses are constructed with sequences from multiple serotypes, then oncolytic potency increases, but the manufacturing and characterization difficulty increases
Solution Approach 1:
The patent optimizes specific parameters such as the ratio of parental serotype sequences in the chimera, the choice of serotype combinations, and the structure of hybrid genes to maximize oncolytic activity while maintaining manufacturability
Data Source
AI summary
The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.